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Abstract
Background Cachexia, also known as muscle wasting, is a
complex metabolic condition characterized by loss of
skeletal muscle and a decline in physical function. Muscle
wasting is associated with cancer, sarcopenia, chronic
obstructive pulmonary disease, end-stage renal disease,
and other chronic conditions and results in significant
morbidity and mortality. GTx-024 (enobosarm) is a nonste-
roidal selective androgen receptor modulator (SARM) that
has tissue-selective anabolic effects in muscle and bone,
while sparing other androgenic tissue related to hair growth
in women and prostate effects in men. GTx-024 has
demonstrated promising pharmacologic effects in preclini-
cal studies and favorable safety and pharmacokinetic
profiles in phase I investigation.
Methods A 12-week double-blind, placebo-controlled
phase II clinical trial was conducted to evaluate GTx-024
in 120 healthy elderly men (>60 years of age) and
postmenopausal women. The primary endpoint was total
leanbodymassassessedbydualenergyX-rayabsorptiometry,
and secondary endpoints included physical function, body
weight, insulin resistance, and safety.
Results GTx-024 treatment resulted in dose-dependent
increases in total lean body mass that were statistically
significant (P<0.001, 3 mg vs. placebo) and clinically
meaningful. There were also significant improvements in
physical function (P=0.013, 3 mg vs. placebo) and insulin
resistance (P=0.013, 3 mg vs. placebo). The incidence of
adverse events was similar between treatment groups.
Conclusion GTx-024 showed a dose-dependent improve-
ment in total lean body mass and physical function and was
well tolerated. GTx-024 may be useful in the prevention
and/or treatment of muscle wasting associated with cancer
and other chronic diseases.
Keywords Muscle wasting.Selective androgen receptor
modulator.Cachexia.Physical function.Lean body mass
1 Introduction
Skeletal muscle accounts for nearly half of whole body
protein mass and plays a critical role in overall health by
providing strength for daily physical function [1]. In
healthy individuals, skeletal muscle homeostasis requires a
balance of anabolic and catabolic processes, resulting in
continuous renewal of muscle proteins without a net change
in overall muscle mass. As the primary reservoir of amino
acids, muscle is the mediator of whole body protein and is a
source of precursors for hepatic gluconeogenesis.
Muscle also plays an important role in blood glucose
regulation and metabolic health [2]. Muscle loss is a strong
predictor of physical disability, frailty, and loss of indepen-
dence and has been linked to poor balance, decreased gait
speed, falls, and fractures [3–6]. Healthy adults lose
approximately 1–2% of their skeletal muscle mass per year
after the age of 50 [7]. Additionally, Baumgartner et al.
estimates that 13–24% of persons under the age of 70 and
up to 50% of individuals over the age of 80 suffer from
significant muscle loss [8].
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chronic conditions including cancer, chronic kidney disease,
diabetes, acquired immune deficiency syndrome, chronic
obstructive pulmonary disease, congestive heart failure,
rheumatoid arthritis and hypogonadism, sepsis, and burn
injury [1, 9–12]. Patients have profound muscle loss because
of increased protein demand, a heightened inflammatory
state, increased resting energy expenditure, and atrophy from
disuse. Muscle wasting is an independent risk factor for poor
health outcomes in patients with chronic diseases [11]. The
prevalence of muscle wasting in cancer patients increases to
greater than 80% prior to death from malignancy and
represents the cause of death in over 20% of cancer patients
[13–16]. To date, no therapy is approved for the prevention
and treatment of muscle wasting.
Although anabolic steroids and testosterone have been
used to treat muscle wasting, their risks often outweigh the
potential benefits for many patients [17]. The use of these
agents is limited by their inability to separate the desired
anabolic effects of steroids in the muscle and bone from
unwanted side effects of testosterone, partly due its
conversion to estrogen in adipose tissue and dihydrotestos-
terone (DHT) in the skin and prostate [18]. Concerns
related to increased risk or severity of benign prostatic
hyperplasia or prostate cancer in men, virilization in
women, and cardiovascular side effects in certain popula-
tions limit widespread use of testosterone and other
anabolic steroids [19]. Additionally, due to limitations in
oral bioavailability, testosterone replacement therapy is only
available in transdermal and intramuscular formulations
which may also limit its usefulness due to adverse skin
reactions and wide fluctuations in the serum concentrations
of testosterone that are observed [20].
There is an unmet medical need for an anabolic agent
with an improved benefit/risk profile. The ideal agent
should demonstrate anabolic selectivity in muscle and bone
without suppressing luteinizing hormone (LH), lack cross-
reactivity with other steroid receptors, allow oral dosing,
and avoid conversion to DHT and estradiol [21]. The need
for such an agent has stimulated the development of
selective androgen receptor modulators (SARMs).
GTx-024 (enobosarm; United States Adopted Names
Council official generic name) is an orally bioavailable
nonsteroidal SARM with tissue-selective anabolic and
androgenic pharmacologic activity [22–26]. In animal
studies, GTx-024 increased muscle mass and bone density
while having limited effects on other androgen-responsive
tissues including the prostate and seminal vesicles. In fact,
prostate size was reduced at doses that increased muscle
mass in intact, male rats. In a phase I study in 48 healthy
18- to 45-year-old males and 23 elderly males with truncal
obesity, GTx-024 administered for 14 days increased lean
body mass and had a favorable tolerability profile without
clinically apparent adverse effects involving the skin or
prostate (data on file). A phase II, randomized, double-
blind, placebo-controlled study was conducted to evaluate
the effects of GTx-024 on total lean body mass and
physical function in elderly men and postmenopausal
women. Secondary endpoints included safety of GTx-024,
effects on fat mass, bone mineral density, blood glucose,
and insulin. This study is the first to demonstrate the ability
of a nonsteroidal, orally bioavailable SARM to increase
lean muscle mass and improve physical function.
2 Patients and methods
This was a randomized, double-blind, placebo-controlled,
and multicenter study conducted under the World Medical
AssociationDeclarationofHelsinki,International Conference
on Harmonization Guidance for Good Clinical Practices. The
study documents were reviewed and approved by an
Independent EthicsCommitteeand Medicines andHealthcare
products Regulatory Agency, UK. The study was conducted
from 11 July 2006 to 20 October 2006. The primary endpoint
was to assess the effect of GTx-024 on total lean body mass
measured by dual energy X-ray absorptiometry (DXA).
Secondary endpoints included assessments of the effects of
GTx-024 on physical function measured by the Stair Climb
Test [27], bone mineral density (BMD), body weight, fat
mass and insulin resistance, sebum production, lipids, serum
hormones, hair growth in females (hirsutism), and safety
and tolerability.
The subjects included in this study were healthy
volunteers without evidence of disease recruited from the
general population around the phase I study units in London
(Richmond Pharmacology, Ltd.), Plymouth (Veeda Clinical
Research), and Dundee (Drug Development Solutions,
Limited) in the UK, Belfast in Northern Ireland (MDS
Pharma Services), and Hamburg, Germany (MDS Pharma
Services).Thesubjectswererecruitedthroughadvertisement
and database searches. The subjects were non-obese (body
mass index (BMI) <30) and were not required to have
mobility disability. The subjects were required to sign an
informed consent, agree to return to the study center at least
ten times during the outpatient portion ofthis study,and have
a white blood cell count ≥3,000/mm
3, platelet count
≥100,000/mm
3, serum creatinine ≤1.5 mg/dL, alanine
aminotransferase and aspartate aminotransferase <1.25
times the upper limit of normal, and total bilirubin
<1.5 mg/dL. Females required clinical confirmation of
menopausal status, and males were required to be over
the age of 60 and have a serum prostate specific antigen
of ≤4.0 ng/mL or a negative prostate biopsy (no prostate
cancer) within 6 months of evaluation. The subjects were
not permitted to initiate diet modification or initiate or
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dietary supplementation was provided.
Subjects were randomly assigned to one of five different
dose groups (doses of 0.1, 0.3, 1 and 3 mg of GTx-024 and
placebo) and were instructed to take the study medication
daily for 86 days at approximately the same time each day,
which included a period of approximately 70 days as an
outpatient. The doses for this study were chosen from the
pharmacokinetic, safety and tolerability data from the
previous trials with GTx-024, and the clinical trial material
was provided by GTx, Inc. Each dose group contained 24
subjects and was randomized in a 1:1:1:1:1 fashion.
Randomization was stratified such that each dose group
contained 12 males and 12 females.
A baseline pre-study assessment of the subjects was
completed within 3 days of the first administered dose,
and the final assessment of efficacy was conducted at
day 86. Body composition, including BMD, was assessed
at baseline, day 30, and day 86 by DXA. Physical
function was evaluated using the Stair Climb Test at
baseline, day 30, and day 86 [27]. The Stair Climb Test
requires that step switch pads be placed on steps 1, 4, 8,
and 12. The switch pads record the time for each subject
to proceed up the stairs. Subjects were asked to climb
the stairs, one step at a time as quickly as possible
without assistance, and were asked to only use the
handrail if they felt like they were losing their balance.
Study personnel were instructed not to provide encour-
agement during the test. The height of the stairs, the
subject's weight, and the time interval between each step
pad were recorded. The power exerted was calculated as
follows:
PowerðwattsÞ
¼
ðweightinkgÞ ð riseinstairsoverthe interval measuredinmetersÞ 9:804m=s2
Timeoverthe interval in seconds
Hair growth in females was assessed by a modified
Ferriman–Gallwey Scale [28]. In the modification of this
scale, hair growth was assessed at each of six anatomical
sites: upper lip, chin, upper arms, chest, upper abdomen, and
upper back in the females participating in the protocol. Hair
growth was scored based on a 4-point scale. Scoring was 0
for no terminal hair growth to 4 for maximal hair growth.
Sebum was assessed at baseline and days 30 and 86 using
a DermaLab® handheld dual tape sebum reader module,
Cortex Technology (Denmark). Two sebum measurements
were taken on each test day. The measurements were taken on
the forehead in two distinct areas on each of the mornings.
Dosing was without regard to food intake except on
days 1 and 15 when blood samples for pharmacokinetic
sampling were collected after the subjects had fasted from
approximately 10 h prior to dose until 4 h after dosing and
on day 86 when fasting glucose and insulin were collected
for measurement of insulin resistance, calculated as the
product of fasting glucose and fasting insulin divided by a
constant based on the Homeostasis Model Assessment of
Insulin Resistance (HOMA-IR) [29].
3 Statistical analyses
Subjects included in the analyses were the evaluable
population defined as subjects in the intent-to-treat
population that completed the study. PROC MIXED of
SAS® Version 8.2 [30] was used to estimate and test
treatment effects for changes from baseline to day 86 for
lean body mass, stair climb power, serum hormones, lipids,
glucose and insulin levels, and other lab values, including
changes in alanine aminotransferase (ALT) and aspartate
aminotransferase (AST). Though some endpoints were
measured at day 30, the analyses that are reported reflect
changes from baseline to day 86. Overall treatment effect
estimates and their associated standard errors are the
differences in the least square means between the placebo
arm and the treatment arm reported from a model with
treatment as the only factor. References to estimates,
standard errors, and associated P values within gender are
from models that include treatment arm, gender, and the
treatment by gender interaction terms. The statistical tests
are T tests comparing the cell means of interest. P values
reported are two sided and are unadjusted for multiple
comparisons. P values <0.05 are considered significant.
4 Results
The demographics and anthropometric characteristics of the
subjects are summarized in Table 1. Mean age of the study
population was 63.3±5.6 years, with no statistically
significant differences between treatment groups. There
were no differences in body weight, height, or BMI
between treatment groups. One hundred and 15 subjects
completed the study. Five subjects were discontinued from
the study prior to completion. Three subjects withdrew
consent due to personal reasons (one subject receiving the
0.3-mg dose and two subjects receiving the 1-mg dose of
GTx-024). One subject was discontinued due to an adverse
event of urinary tract infection after a single dose of GTx-024
(1-mgdose).Onesubjectwasdiscontinuedbytheinvestigator
duetoALTelevation(3-mgdose).However,theALTelevation
was not considered a serious adverse event.
As shown in Fig. 1, GTx-024 elicited a dose-dependent
increase in total lean body mass, with subjects in the
3-mg-dose group gaining a statistically significant (P<0.001)
average of 1.3 kg±0.3 (±1 SE) of lean mass compared to
placebo (Table 2). The change in lean mass at the 1-mg dose
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statistically significant (P=0.055). A statistically significant
(P=0.049) decrease in total fat mass was also observed at the
3-mg dose, with the 1-mg dose approaching statistical
significance (P=0.085). The differences in changes in fat
mass from baseline in the 3-mg group compared to placebo
were similar in males and females with approximately a loss
of 0.6 kg relative to placebo. No differences in total body
weight were observed, indicating that the shift to more lean
body composition in the 3-mg-dose group was achieved, at
least partially, at the expense of body fat.
GTx-024 demonstrated a dose-dependent decrease in the
time required for elderly men and postmenopausal women
to climb 12 steps. The reduction in time was observed at
every segment of the stair climb (i.e., 1–4, 4–8, 8–12, and
1–12 stairs; data not shown) within the GTx-024 3-mg-dose
group. A statistically significant (P=0.013) improvement in
stair climb power was observed in the GTx-024 3-mg-dose
group (Fig. 2).
GTx-024 3 mg significantly (P=0.006) decreased blood
glucose an average of 6.9±2.5 (milligrams per deciliter),
while a trend toward a significant (P=0.052) reduction of
2.2±1.1 μIU/mL in blood insulin was also observed in
this group compared to placebo. Additionally, insulin
resistance (calculated based on the HOMA-IR [29]) was
reduced in the GTx-024 1-mg and 3-mg treatment groups
(placebo=2.6%±8.6, 1 mg=−9.3%±5.5, 3 mg=−27.5%±7.6:
P=0.013 3 mg vs. placebo).
The incidence of adverse events was similar among
groups and between GTx-024- and placebo-treated subjects.
The most common adverse events were headache and back
pain (Table 3). No SAEs were reported during the study.
Decreases in serum triglycerides were noted in the GTx-
024 1- and 3-mg-dose groups compared to placebo, with
the 3-mg-dose group approaching statistical significance
(Table 4). A statistically significant reduction in total
cholesterol was observed in the 0.3-, 1-, and 3-mg GTx-
024 dose groups compared to placebo. No significant effect
on low-density lipoprotein (LDL) was observed among
treatment groups. High-density lipoprotein (HDL) was
reduced in a dose-dependent manner in GTx-024-treated
subjects compared to placebo, with 17% and 27% decreases
noted at the 1- and 3-mg doses, respectively. Importantly,
the average total cholesterol/HDL ratio in the 1-mg- and
3-mg-dose groups was between 3.5 and 5 at baseline and
end of the study.
In men, no statistically significant differences from
placebo in change from baseline values for free testosterone,
DHT, estradiol, follicle-stimulating hormone (FSH), or LH
Table 1 Patient demographics
Placebo 0.1 mg 0.3 mg 1 mg 3 mg
n=24 n=24 n=24 n=24 n=24
Gender
Female 12 (50.0%) 12 (50.0%) 12 (50.0%) 12 (50.0%) 12 (50.0%)
Male 12 (50.0%) 12 (50.0%) 12 (50.0%) 12 (50.0%) 12 (50.0%)
Race
Black/African American 0 (0.0%) 1 (4.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other 1 (4.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
White 23 (95.8%) 23 (95.8%) 24 (100%) 24 (100%) 24 (100%)
Age (years)
Median (min, max) 62.5 (48,70) 62.5 (52,79) 63.5 (52,76) 64.0 (48,79) 64.5 (55,74)
Weight (kg)
Median (min, max) 68.95 (56.1, 94.0) 74.9 (52.2, 93.8) 69.95 (50.7, 106.3) 76.4 (49.0, 100.7) 70.55 (50.1, 97.3)
Height (cm)
Median (min, max) 166.5 (153, 186) 164.8 (149, 187) 167.0 (153, 184) 173.5 (152, 191) 168.0 (151, 187)
BMI (kg/m
2)
Median (min, max) 25.15 (20.8, 31.0) 26.85 (21.5, 31.6) 24.80 (19.6, 31.4) 26.05 (19.1, 31.4) 21.35 (20.1, 30.7)
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Fig. 1 Percentage change from baseline to day 86/EOS in total lean
body mass: evaluable population. EOS end of study, *P<0.001 3 mg
vs. placebo (T test)
156 J Cachexia Sarcopenia Muscle (2011) 2:153–161were observed at any GTx-024 dose. However, sex hormone-
binding globulin (SHBG) was significantly (P=0.048)
reduced with GTx-024 3 mg versus placebo, −15.8±
7.9 nmol/L. The decrease in SHBG was accompanied by
a reduction of serum total testosterone in subjects treated
w i t h1m g( P< 0 . 0 0 1 )o r3m g( P< 0 . 0 0 1 )o fG T x - 0 2 4
compared to placebo, −6.4±1.1 nmol/L and −7.4±1.0
(Table 5).
In women, changes from baseline in free testosterone,
total testosterone, DHT, and estradiol levels did not differ
between GTx-024 and placebo. Observed decreases in LH
and FSH in women with GTx-024 3 mg versus placebo
were statistically significant, but the reduction in LH and
FSH in postmenopausal women had no effect on other
serum hormones. SHBG was significantly reduced with
GTx-024 1 mg (P<0.001) and 3 mg (P<0.001) compared
to placebo, −39.3±8.4 and −36.4±8.2 nmol/L, respectively
(Table 5).
GTx-024 did not have effects on sebum production or
hair growth in women. Results of clinical laboratory tests
were generally unremarkable. No significant increases in
all
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Fig. 2 Percentage change from baseline to day 86/EOS in stair climb
power: evaluable population. EOS end of study, *P=0.0133 mg vs.
placebo (T test)
Baseline SD Absolute change SD P value treatment
versus placebo
Lean body mass (g)
Placebo 44,614.8 9,674.22 −73.2 1,126.77
0.1 mg 46,399.5 9,350.43 164 868.19 0.474
0.3 mg 45,257.8 10,102.75 78 1,150.33 0.651
1 mg 48,145.3 10,589.96 588.7 1,257.47 0.055
3 mg 45,030.7 10,255.4 1,246.3 1,287.92 <.001*
Fat mass (g)
Placebo 20,806.6 8,688.95 304.7 1,105.24
0.1 mg 23,354.5 6,019.07 222.7 958.04 0.793
0.3 mg 21,554.8 6,693.72 −65.4 1,054.9 0.242
1 mg 22,561.4 5,659.38 −255.1 947.95 0.085
3 mg 20,492.9 6,932.34 −321.9 1,281.95 0.049*
Total body weight (kg)
Placebo 68.0 12.01 −0.1 2.32
0.1 mg 72.5 10.61 0.4 1.28 0.51
0.3 mg 68.6 15.87 0.9 4.88 0.196
1 mg 72.9 13.65 0.3 1.67 0.55
3 mg 67.5 13.48 0.9 1.74 0.178
Stair climb speed (s)
Placebo 5.0003 1.24036 −0.2 0.84768
0.1 mg 4.3008 1.09389 0.6 1.788 0.010*
0.3 mg 4.3789 1.17799 0 0.79584 0.507
1 mg 4.7289 1.04263 −0.2 0.78467 0.953
3 mg 4.9847 1.59781 −0.8 0.86947 0.08
Power (W)
Placebo 280.72 87.807 20.35 38.835
0.1 mg 331.77 91.95 −16.68 60.608 0.012*
0.3 mg 307.47 96.69 14.45 49.106 0.69
1 mg 324.7 100.826 10.68 50.955 0.522
3 mg 298.69 97.232 49.67 50.317 0.049*
Table 2 Changes in primary
and secondary endpoints
*P<0.05
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any GTx-024 dose. Small, statistically significant increases in
hemoglobin and hematocrit were observed with GTx-024
3 mg compared to placebo. Although transient increases in
ALTtoabovetheupperlimitofnormalwereobservedineight
subjects in this study, the ALT observations in seven of eight
subjects had resolved while on drug such that no subject had
clinically significantly, abnormal levels of ALTor ASTat the
endofstudy.Onesubjectwasdiscontinuedduetoanelevation
in ALT 4.2 times the upper limit of normal. The ALT level in
that subject returned to normal levels after discontinuation of
the study drug.
Baseline SD Absolute change SD P value
Total cholesterol (mg/dL)
Placebo 195.9 35.83 4.8 17.46
0.1 mg 197.8 27.31 −6.3 20.03 0.088
0.3 mg 204.4 29.84 −14.3 19.88 0.004*
1 mg 197.1 29.87 −19 26.34 <.001*
3 mg 203.1 35.1 −15.3 26.95 0.003*
HDL (mg/dL)
Placebo 49.9 10.2 0 4.88
0.1 mg 50.9 9.49 −4.3 4.72 0.027*
0.3 mg 55.3 13.99 −6.3 4.86 0.001*
1 mg 52.1 10.44 −8.9 6.18 <.001*
3 mg 52.8 10.99 −14.7 10.58 <.001*
LDL (mg/dL)
Placebo 130 34.02 7.5 13.95
0.1 mg 128 22.91 5.5 16.48 0.734
0.3 mg 130.7 31.57 −0.2 15.67 0.206
1 mg 125.2 23.83 3.9 27.16 0.564
3 mg 130.6 29.68 4.6 27.44 0.629
Triglycerides (mg/dL)
Placebo 114.8 39.66 7.2 34.43
0.1 mg 137.4 76.17 5.8 46.96 0.952
0.3 mg 126 80.69 2.4 50.18 0.838
1 mg 112.9 49.14 −12.8 31.14 0.4
3 mg 153.5 182.89 −36.6 155.64 0.06
Table 4 Summary of
lipid parameters
Adverse event frequency by treatment
Number of subjects reporting event (%)
Placebo 0.1 mg 0.3 mg 1 mg 3 mg
Nausea 2 (8.3%) 2 (8.3%) 5 (20.8%) 3 (12.5%) 1 (4.2%)
Diarrhea 3 (12.5%) 2 (8.3%) 5 (20.8%) 6 (25.0%) 2 (8.3%)
Fatigue 2 (8.3%) 1 (4.2%) 3 (12.5%) 0 (0.0%) 2 (8.3%)
Influenza-like illness 2 (8.3%) 3 (12.5%) 1 (4.2%) 0 (0.0%) 0 (0.0%)
Nasopharyngitis 3 (12.5%) 2 (8.3%) 3 (12.5%) 4 (16.7%) 0 (0.0%)
Alanine aminotransferase increase 0 (0.0%) 1 (4.2%) 0 (0.0%) 1 (4.2%) 5 (20.8%)
Back pain 4 (16.7%) 4 (16.7%) 1 (4.2%) 9 (37.5%) 3 (12.5%)
Pain in extremity 6 (25.0%) 2 (8.3%) 2 (8.3%) 3 (12.5%) 1 (4.2%)
Headache 4 (16.7%) 7 (29.2%) 7 (29.2%) 9 (37.5%) 5 (20.8%)
Cough 1 (4.16%) 1 (4.2%) 3 (12.5%) 3 (12.5%) 1 (4.2%)
Pharyngolaryngeal pain 3 (12.5%) 2 (8.3%) 2 (8.3%) 2 (8.3%) 3 (12.5%)
Table 3 Summary of
adverse events
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Muscle wasting is associated with significant morbidity and
mortality [11, 13, 14]. The potential risk profile of
testosterone replacement therapy and anabolic steroids
limits their clinical use for a variety of indications that
may otherwise benefit from increasing lean mass, improved
physical function, and improved insulin resistance. SARMs
in various stages of preclinical and clinical drug develop-
ment offer an important option to meet these unmet medical
needs [25, 26].
GTx-024isthefirstSARMtoreachadvancedclinicaltrials
and demonstrate a strong efficacy and safety profile [21]. In
this randomized, double-blind, placebo-controlled study,
GTx-024 increased total lean body mass and improved
physical function with no evidence of androgenic side effects
in elderly men and postmenopausal women. The increase in
total lean body mass with GTx-024 was accompanied by an
Table 5 Summary of changes in serum hormones
Male Female
Baseline SD Absolute change SD P value Baseline SD Absolute change SD P value
Free testosterone (pmol/L)
Placebo 43.57 20.5 −11.21 17.97 7.16 4.75 −0.27 0.87
0.1 mg 25.55 9.78 0.54 7.89 0.003* 7.25 5.05 −2 3.06 0.718
0.3 mg 22.13 10.37 2.06 8.33 <.001* 6.63 3.6 −0.4 1.97 0.887
1 mg 39.63 10.84 −11.03 6.71 0.966 5.41 4.38 −0.24 0.61 0.922
3 mg 36.5 16.56 −8.24 7.64 0.413 5.64 2.94 −1.4 0.995
Total testosterone (nmol/L)
Placebo 18.98 5.05 0.5 3.39 1.05 0.45 −0.03 0.35
0.1 mg 12.76 2.33 −0.49 2.05 0.348 0.96 0.34 −0.02 0.25 0.995
0.3 mg 16.18 4.99 −1.8 4.2 0.053 1.07 0.5 −0.04 0.32 0.981
1 mg 19.65 6.58 −6.03 3.9 <.001* 0.95 0.41 −0.09 0.31 0.909
3 mg 16.02 5.59 −6.86 3.51 <.001* 0.93 0.58 −0.17 0.21 0.918
SHBG (nmol/L)
Placebo 51.17 20.61 −10.03 8.62 68.6 40.39 −16.5 28.42
0.1 mg 36.25 14.34 −6.09 7.02 0.627 47.67 15.26 −1.09 16.98 0.064
0.3 mg 44.58 11.2 −11.36 10.88 0.775 62.92 17.53 −21.17 16.73 0.564
1 mg 48.3 20.73 −18.81 15.76 0.265 83 37.63 −51.84 35.95 <.001*
3 mg 42.28 13.9 −25.82 9.32 0.048* 64.61 25.55 −51.95 24.3 <.001*
FSH (IU/L)
Placebo 6.02 2.1 −0.14 0.8 66.73 35.55 −1.54 5.86
0.1 mg 6.63 5.9 −0.24 1.43 0.978 74.58 17.99 2.78 10.32 0.216
0.3 mg 7.59 5.22 −0.23 0.57 0.968 82.28 32.98 −4.45 20.11 0.393
1 mg 5.96 2.55 −0.97 2 0.929 91.72 25.61 −5.11 7.19 0.25
3 mg 7.58 5.39 −1.03 0.74 0.791 82.31 33.02 −9.82 5.5 0.014*
LH
Placebo 3.58 1.3 0.4 1.51 25.04 12.45 −3.32 4.13
0.1 mg 4.19 2.57 −0.75 0.77 0.466 23.01 5.42 1.15 4.69 0.010*
0.3 mg 5.24 2.57 −0.01 1.68 0.834 29.23 9.54 −1.75 5.27 0.403
1 mg 4.34 1.11 −1 1.69 0.476 37.46 9.96 −1.63 6.66 0.78
3 mg 4.83 1.74 −0.54 1.59 0.543 31.74 12.39 −5.5 6.23 0.039*
Estradiol (pmol/L)
Placebo 111.26 29.27 −14.96 21.95 190.21 294.96 −141.26 309.5
0.1 mg 115.83 47.84 −21 28.75 0.775 91.18 32.89 −5.63 12.51 0.021*
0.3 mg 114.2 28.15 −14.38 23.85 0.988 77 6.23 −3.25 7.89 0.013*
1 mg 125.04 30.99 −32.28 28.65 0.679 107.12 104.86 −28.22 31.03 0.045*
3 mg 120.84 26.3 −44.21 27.67 0.472 139.57 170.14 −47.29 98.64 0.014*
J Cachexia Sarcopenia Muscle (2011) 2:153–161 159improvement in physical function as demonstrated by a
clinically meaningful improvement in the Stair Climb Test.
GTx-024 3 mg also significantly reduced fasting glucose
levels, and a trend toward reduction in blood insulin was
observed. These effects resulted in a decrease in insulin
resistance from baseline in the 1-mg and 3-mg treatment
groups calculated based on the HOMA-IR. Of note, such
decrease in insulin resistance was similar to that observed
with metformin and glipizide, drugs used in the treatment
of diabetes [31, 32]. Low levels of testosterone in men are
associated with insulin resistance and type II diabetes,
while testosterone therapy is known to improve metabolic
parameters [33–35]. This observation may have potential
implications for the use of SARMs in prediabetic or
diabetic individuals, as commonly seen in patients with
chronic kidney disease, chronic obstructive pulmonary
disease, or metabolic syndrome [36–38].
GTx-024 was well tolerated with an adverse event
profile similar to placebo during 3 months of daily
treatment. Compared to placebo, GTx-024 decreased total
cholesterol, HDL, and triglycerides. These findings are
consistent with previous reports that oral anabolic therapy
influences serum lipid profiles [39, 40]; however, it is
important to note that the average LDL/HDL ratio for all
GTx-024 doses remained in the low cardiovascular risk
category. Furthermore, the beneficial effects of GTx-024 on
insulin sensitivity and triglycerides, known associations of
hypogonadism with metabolic syndrome and cardiovascu-
lar risk [33–35], as well as the low cardiovascular risk
observed in randomized clinical trials of testosterone
supplementation [18], suggest that the overall cardiovascu-
lar risk/benefit ratio for GTx-024 is low.
The pharmacologic effects of GTx-024 on serum hormone
levels were unremarkable. Notable but expected reductions in
SHBG and total testosterone in men were observed. The
reductions in SHBG in men and women (−61% and −80%,
respectively, at the 3-mg dose) exceed those observed in men
treated with a 600-mg intramuscular testosterone enanthate
(−31%)[41]. Decreases in total testosterone accompanied the
observed decreases in SHBG; however, no significant
decreases in free testosterone were observed in men or
women at any dose of GTx-024. GTx-024-associated
reductions in FSH and LH that were observed in postmen-
opausal women were not clinically significant.
In this 3-month study, GTx-024 showed no difference in
BMDcomparedtoplacebo(data not shown).Changes inBMD
werenotnecessarilyexpectedasthetreatmentperiodwaslikely
too short to detect a benefit. In preclinical studies, GTx-024
demonstrated both anabolic and antiresorptive activity in bone.
Future research is warranted as the potential dual beneficial
effects of GTx-024 and other SARMs on muscle and bone may
provide a unique advantage to currently available agents for
osteoporosis that solely modify bone strength.
6 Conclusion
There are currently no approved therapies available for the
prevention or treatment of muscle wasting. GTx-024 is a
novel SARM that was well tolerated in elderly men and
postmenopausal women and resulted in significant
increases in total lean body mass and improvements in
physical function. Importantly, this study provides evidence
that GTx-024 provides beneficial anabolic effects on total
lean body mass and physical function without the adverse
consequences often seen with testosterone and other
anabolic steroids. These data support the development of
GTx-024 for treatment and prevention of muscle wasting in
patients with chronic diseases.
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